Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as the principal hepatic manifestation of obesity and metabolic dysfunction. Its pathogenesis is complex and multifactorial, driven by insulin resistance, low-grade chronic inflammation, oxidative stress, gut microbio...

Descripció completa

Dades bibliogràfiques

Autors principals:	Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2026-05-01
Col·lecció:	Biomolecules
Matèries:	MASLD obesity cACLD SGLT-2I GLP-1 RA GLP1/G
Accés en línia:	https://www.mdpi.com/2218-273X/16/6/797
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!